Brief: Mendus And UMCG Announce Positive Topline Data From Alison Trial

Mendus AB (publ)

18/12/2024 07:04

Dec 18 (Reuters) - Mendus AB (publ)  IMMUN.ST :
    * MENDUS AND UMCG ANNOUNCE POSITIVE TOPLINE DATA FROM THE
ALISON
TRIAL WITH VIDIDENCEL IN OVARIAN CANCER
    * DATA COLLECTED CONFIRM THAT VIDIDENCEL STIMULATES IMMUNE
RESPONSES AGAINST OVARIAN CANCER ANTIGENS, AS A POTENTIAL BASIS
FOR AN EFFECTIVE ANTI-TUMOR RESPONSE

Source text:  ID:nMFN4mKl3h 
Further company coverage:  IMMUN.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))